Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Surrozen is a clinical-stage biotechnology company focused on discovering and developing a new class of targeted therapeutics to selectively modulate the Wnt pathway. The Wnt pathway is a fundamental biological pathway involved in tissue repair and regeneration. Surrozen's mission is to leverage its proprietary antibody-based technologies to create breakthrough medicines for patients with severe liver diseases, inflammatory bowel disease (IBD), and other conditions where tissue injury or degeneration is a primary cause. Their lead candidates, SZN-043 for severe liver diseases and SZN-413 for retinal diseases, aim to address significant unmet medical needs by promoting tissue regeneration.
The headquarters serves as the primary center for Surrozen's research, clinical development, operations, and corporate administration.
Located within a modern biotechnology campus, the facility likely includes advanced laboratory spaces for drug discovery and development, alongside office areas designed to foster collaboration.
Surrozen cultivates a science-driven, innovative, and collaborative work environment. The team is dedicated to advancing novel therapeutics with a focus on rigorous scientific research and addressing patient needs.
The South San Francisco location provides strategic advantages, including access to a rich talent pool of scientists and biotech professionals, proximity to leading academic and research institutions, and a vibrant ecosystem of venture capital and industry partners.
While Surrozen's core operations are based in its South San Francisco headquarters, the company engages in activities with a global reach, particularly concerning its clinical trials which may involve sites in multiple countries. As its therapeutic candidates advance, Surrozen may establish international collaborations or partnerships for further development and commercialization efforts worldwide. Its research targets diseases affecting patient populations globally.
181 Oyster Point Blvd, Suite 200
South San Francisco
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Surrozen' leadership includes:
Surrozen has been backed by several prominent investors over the years, including:
Over the past 12 months, Surrozen has strategically strengthened its executive leadership team with key appointments, including a new Chief Financial Officer and a new Chief Medical Officer, alongside an internal promotion to Chief Technical Operations Officer. These changes reflect the company's focus on advancing its clinical programs and operational capabilities.
Discover the tools Surrozen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Surrozen's common email format appears to be the first initial of the employee's first name followed directly by their last name, preceding the '@surrozen.com' domain. This is a standard convention in many corporations.
flast@surrozen.com (e.g., jdoe@surrozen.com)
Format
cslattery@surrozen.com
Example
85%
Success rate
Surrozen, Inc. / GlobeNewswire • May 6, 2024
Surrozen announced the presentation of new preclinical data for SZN-413, its Fzd4-targeted Wnt agonist, highlighting its potential in treating retinal vascular-associated diseases. The data was shared at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting....more
Surrozen, Inc. / GlobeNewswire • March 26, 2024
Surrozen reported the dosing of the first patient in its Phase 1b clinical trial evaluating SZN-043 in patients suffering from severe alcoholic hepatitis. This trial aims to assess the safety, tolerability, and pharmacodynamics of SZN-043, a hepatocyte-targeted R-spondin mimetic....more
Surrozen, Inc. / GlobeNewswire • February 29, 2024
Surrozen released its financial results for the fourth quarter and full year ended December 31, 2023. The company also provided a corporate update, detailing progress in its pipeline programs, SZN-043 for liver disease and SZN-413 for retinal disease, and its financial position....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Surrozen, are just a search away.